DOI: 10.5176/2345-783X_PHARMA16.11

Authors: Kinga Sałat, Adriana Rojek, Ewelina Wojcieszak, Robert Sałat, Adrian Podkowa, Felix Kern, Jörg Pabel, Klaus T. Wanner, Katarzyna Kulig


The aim of this research was to investigate antiallodynic and antihyperalgesic properties of a newly synthesized and more potent (5 nM) than tiagabine GAT1 inhibitor, named DDPM-2571, in two mouse models of neuropathic pain, i.e., a model of streptozotocin (STZ)-induced painful diabetic neuropathy, and chemotherapy-induced peripheral neuropathy caused by oxaliplatin. Preliminary safety pharmacology studies of DDPM-2571 in neuropathic animals were also conducted using locomotor activity, rotarod and passive avoidance tests.

Keywords: GABA transporter isoform 1 neuropathic pain safety pharmacology


Price: $0.00

Loading Updating cart...